Journal of General Internal Medicine

, Volume 13, Issue 4, pp 243–250 | Cite as

Correlates and prevalence of benzodiazepine use in community-dwelling elderly

  • Patrick P. Gleason
  • Richard Schulz
  • Nicholas L. Smith
  • Jason T. Newsom
  • Patricia D. Kroboth
  • Frank J. Kroboth
  • Bruce M. Psaty
Original Articles

Abstract

OBJECTIVE: To describe the prevalence of benzodiazepine use, sociodemographic and physical health factors associated with use, dosages taken, and directions for use among individuals aged 65 years and older.

DESIGN: Cross-sectional analysis of baseline data from the community-based, prospective observational Cardiovascular Health Study.

PATIENTS/PARTICIPANTS: Medicare eligibility lists from four U.S. communities were used to recruit a representative sample of 5,201 community-dwelling elderly, of which 5,181 participants met all study criteria.

MEASUREMENTS AND MAIN RESULTS: Among participants, 511 (9.9%) were taking at least one benzodiazepine, primarily anxiolytics (73%). Benzodiazepines were often prescribed to be taken pro re nata (PRN “as needed”), and 36.5% of prescriptions with instructions to be taken regularly were taken at a dose lower than prescribed. Reported over-the-counter (OTC) sleep aid medication use was 39.2% in benzodiazepine users and 3.3% in nonusers. In a multivariate logistic model, the significant independent correlates of benzodiazepine use were being white (odds ratio [OR] 1.9; 95% confidence interval [CI] 1.0, 3.4), female (OR 1.7; CI 1.4, 2.2), and living in Forsyth County, North Carolina, or Washington County, Maryland, compared with living in Sacramento County, California, or Allegheny County, Pennsylvania (OR 2.3; CI 1.4, 2.2); having coronary heart disease (OR 1.6; CI 1.2, 2.1), health status reported as poor or fair (OR 1.8; CI 1.4, 2.3), self-reported diagnosis of nervous or emotional disorder (OR 6.7; CI 5.1, 8.7), and reporting use of an OTC sleep aid medication (OR 18.7; CI 14.1, 24.7).

CONCLUSIONS: One in 10 participants reported taking a benzodiazepine, most frequently an anxiolytic, often at a lower dose than prescribed and usually PRN. The high prevalence of OTC sleep aid medication and benzodiazepine use may place the patient at increased risk of psychomotor impairment. Physicians should assess OTC sleep aid medication use when prescribing benzodiazepines.

Key words

benzodiazepine sleep aid medication over-the-counter Cardiovascular Health Study elderly anxiolytics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gillin JC, Byerley WF. The diagnosis and management of insomnia. N Engl J Med. 1990;322:239–48.PubMedCrossRefGoogle Scholar
  2. 2.
    Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med. 1993;328:1398–1405.PubMedCrossRefGoogle Scholar
  3. 3.
    Kales A, Bixler EO, Soldatos CR, Vela-Bueno A, Jacoby JA, Kales JD. Quazepam and temazepam: effect of short- and intermediate-term use and withdrawal. Clin Pharmacol Ther. 1986;39:345–52.PubMedCrossRefGoogle Scholar
  4. 4.
    Mendelson WB, Weingartner H, Greenblatt DJ, Garnett D, Willin JC. A clinical study of flurazepam. Sleep. 1982;5:350–60.PubMedGoogle Scholar
  5. 5.
    Cross-National Collaborative Panic Study, Second Phase Investigators. Drug treatment of panic disorder, comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry. 1992;160:191–202.Google Scholar
  6. 6.
    Rickels K, Schweizer E, Csanalosi I, Case WG, Chung H. Long term treatment of anxiety and risk of withdrawal: prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry. 1988;45:444–50.PubMedGoogle Scholar
  7. 7.
    Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Clin Pharmacokinet. 1991;21:262–73.PubMedGoogle Scholar
  8. 8.
    Bertz RJ, Kroboth PD, Kroboth FJ, et al. Alprazolam in elderly and young men. Sensitivity and tolerance to psychomotor, sedative and memory effects. J Pharmacol Exp Ther. 1997;281:1317–29.PubMedGoogle Scholar
  9. 9.
    Greenblatt DJ, Harmatz JS, Shapiro L, Engelhardt N, Gouthro TA, Shader RI. Sensitivity to triazolam in the elderly. N Engl J Med. 1991;324:1691–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Smith RB, Divoll M, Gillespie WR, Greenblatt DJ. Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam. J Clin Psychopharmacol. 1983;3:172–6.PubMedGoogle Scholar
  11. 11.
    Greenblatt DJ, Divoll M, Abernethy DR, Ochs HR, Shader RI. Benzodiazepine kinetics: implication for therapeutics and pharmacogeriatrics. Drug Metab Rev. 1983;14:251–92.PubMedGoogle Scholar
  12. 12.
    Greenblatt DJ, Divoll M, Harmatz JS, McLaughlin DS, Shader RI. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther. 1981;30:475–86.PubMedCrossRefGoogle Scholar
  13. 13.
    Greenblatt DJ, Allen MD, Shader RI. Toxicity of high-dose flurazepam in the elderly. Clin Pharmacol Ther. 1977;21:355–61.PubMedGoogle Scholar
  14. 14.
    Kruse WHH. Problems and pitfalls in the use of benzodiazepines in the elderly. Drug Safety. 1990;5:328–44.PubMedGoogle Scholar
  15. 15.
    Olfson M, Pincus HA. Use of benzodiazepines in the community. Arch Intern Med. 1994;154:1235–40.PubMedCrossRefGoogle Scholar
  16. 16.
    Stewart RB, Franklin EM, Moore MT, Hale WE. Changing patterns of psychotropic drug use in the elderly: a five-year update. DICP Ann Pharmacother. 1989;23:610–3.Google Scholar
  17. 17.
    Wysowski DK, Baum C. Outpatient use of prescription sedative-hypnotic drugs in the United States, 1980 through 1989. Arch Intern Med. 1991;151:1779–83.PubMedCrossRefGoogle Scholar
  18. 18.
    Hindmarch I, Kerr JS, Sherwood N. The effects of alcohol and other drugs on psychomotor performance and cognitive function. Alcohol Alcoholism. 1991;26:71–9.Google Scholar
  19. 19.
    Ellinwood EH Jr, Heatherly DG, Nikaido AM, Bjornsson TD, Kitls C. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam, and diazepam. Psychopharmacology (Berl). 1985;86:392–9.CrossRefGoogle Scholar
  20. 20.
    Smith RB, Kroboth PD, Vanderlugt JT, Phillips JP, Juhl RP. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology (Berl). 1984;84:452–6.CrossRefGoogle Scholar
  21. 21.
    Linnoila M, Erwin CW, Brendle A, Simpson D. Psychomotor effects of diazepam in anxious patients and healthy volunteers. J Clin Psychopharmacol. 1983;3:88–96.PubMedCrossRefGoogle Scholar
  22. 22.
    Hemmelgarn B, Suissa S, Huang A, Boivin JF, Pinard G. Benzodiazepine use and the risk of motor vehicle crash in elderly. JAMA. 1997;278:27–31.PubMedCrossRefGoogle Scholar
  23. 23.
    Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA. 1989;262:3303–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Granek E, Baker SP, Abbey H, et al. Medications and diagnosis in relation to falls in a long-term care facility. J Am Geriatr Soc. 1987;35:503–11.PubMedGoogle Scholar
  25. 25.
    Rubenstein LZ, Josephson KR, Robbins AS. Falls in the nursing home. Ann Intern Med. 1994;121:442–51.PubMedGoogle Scholar
  26. 26.
    Ray WA, Griffin MR, Downey W. Psychotropic drug use and the risk of hip fracture. N Engl J Med. 1987;316:363–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med. 1995;332:767–73.PubMedCrossRefGoogle Scholar
  28. 28.
    Herings RMC, Stricker BHC, de Boer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med. 1995;155:1801–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Woods JH, Katz JL, Winger G. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev. 1992;44:151–347.PubMedGoogle Scholar
  30. 30.
    Nolan L, O’Malley K. Patients, prescribing, and benzodiazepines. Eur J Clin Pharmacol. 1988;35:225–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Mayer-Oakes SA, Kelman G, Beers MH, et al. Benzodiazepine use in older, community-dwelling southern Californians: prevalence and clinical observations. Ann Pharmacother. 1993;27:416–21.PubMedGoogle Scholar
  32. 32.
    Swartz M, Landerman R, George LK, Melville ML, Blazer D, Smith K. Benzodiazepine anti-anxiety agents: prevalence and correlates of use in a southern community. Am J Public Health. 1991;81:592–6.PubMedCrossRefGoogle Scholar
  33. 33.
    Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol. 1993;3:358–66.PubMedCrossRefGoogle Scholar
  34. 34.
    Landry JA, Smyer MA, Tubman JG, Lago DJ, Roberts J, Simonson W. Validation of two methods of data collection of self-reported medicine use among the elderly. Gerontologist. 1988;28:672–6.PubMedGoogle Scholar
  35. 35.
    Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M. Assessing the use of medications in the elderly: method and initial results in the Cardiovascular Health Study. J Clin Epidemiol. 1992;45:683–92.PubMedCrossRefGoogle Scholar
  36. 36.
    Schulz R, Mittelmark M, Kronmal R, et al. Predictors of perceived health status in elderly men and women. J Aging Health. 1994;6:419–47.PubMedCrossRefGoogle Scholar
  37. 37.
    Cohen S, Mermelstein R, Kamarack T, Hoberman HM. Measuring the functional components of social support. In: Sarason IG, Sarason BR, eds. Social Support: Theory, Research, and Applications. The Hague, Netherlands: Martinus Nijhoff; 1985:73–94.Google Scholar
  38. 38.
    Katz SC, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The index of ADL: a standardized measure of biological and psychosocial function. JAMA. 1963;185:914–9.PubMedGoogle Scholar
  39. 39.
    Lawton MP, Brod EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179–86.PubMedGoogle Scholar
  40. 40.
    Hosmer DW, Lemeshow S, eds., Applied Logistic Regression. New York, NY: Wiley and Sons; 1989.Google Scholar
  41. 41.
    Simons FE, Simons KJ. The pharmacology and use of H1-receptorantagonist drugs. N Engl J Med. 1994;330:1663–70.PubMedCrossRefGoogle Scholar
  42. 42.
    Simons FER. H1-receptor-antagonists: comparative tolerability and safety. Drug Safety. 1994;10:350–80.PubMedGoogle Scholar
  43. 43.
    Lamy P. Over-the-counter medications: the drug interactions we overlook. J Am Geriatr Soc. 1982;30:S69.Google Scholar
  44. 44.
    Kupfer DJ, Reynolds CF. Management of insomnia. New Engl J Med. 1997;336:341–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Jiang W, Babyak M, Krantz DS, et al. Mental stress-induced myocardial ischemia and cardiac events. JAMA. 1996;275:1651–6.PubMedCrossRefGoogle Scholar
  46. 46.
    Reich J. The epidemiology of anxiety. J Nerv Ment Dis. 1986;174:129–36.PubMedCrossRefGoogle Scholar
  47. 47.
    Chassin MR, Brook RH, Park RE, et al. Variations in the use of medical and surgical services by the medicare population. N Engl J Med. 1986;314:285–90.PubMedCrossRefGoogle Scholar
  48. 48.
    Gilbert K, Gleason PP, Singer DE, et al. Variations in antimicrobial use and costs in more than 2000 patients with community-acquired pneumonia. Am J Med. 1998;104:17–27.PubMedCrossRefGoogle Scholar
  49. 49.
    Mort EA. Clinical decision-making in the face of scientific uncertainty: hormone replacement therapy as an example. J Fam Pract. 1996;42:147–51.PubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine 1998

Authors and Affiliations

  • Patrick P. Gleason
    • 1
    • 3
  • Richard Schulz
    • 2
  • Nicholas L. Smith
    • 5
  • Jason T. Newsom
    • 7
  • Patricia D. Kroboth
    • 1
  • Frank J. Kroboth
    • 3
  • Bruce M. Psaty
    • 4
    • 5
    • 6
  1. 1.Received from the Department of Pharmaceutical SciencesSchool of PharmacyUSA
  2. 2.University Center for Social and Urban ResearchUSA
  3. 3.Division of General Internal Medicine, Department of MedicineUniversity of Pittsburgh
  4. 4.Department of MedicineUniversity of WashingtonSeattle
  5. 5.Department of EpidemiologyUniversity of WashingtonSeattle
  6. 6.Department of Health ServicesUniversity of WashingtonSeattle
  7. 7.Regional Research InstitutePortland (Ore.) State UniversityUSA
  8. 8.School of Pharmacy, Dept. of Pharmaceutical SciencesUniversity of PittsburghPittsburgh

Personalised recommendations